Myriad Genetics, Inc. filed a Form 8-K on November 5, 2026, disclosing that it detected unauthorized access within its information technology network environment on November 2, 2026.
MetaVia Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on November 5, 2026, disclosing positive interim clinical trial data and an updated corporate presentation.
Dropbox, Inc. filed a Form 8-K with the SEC on November 5, 2026, disclosing a definitive agreement to acquire Tigris Data Inc. for approximately $350 million in cash, signed on November 3, 2026, and announcing the launch of a new offering called DBX Agent …
Construction Partners, Inc. filed a Form 8-K on November 5, 2026, disclosing preliminary financial results for the fiscal year ended September 30, 2026, a preliminary outlook for the fiscal year ending September 30, 2027, and the completion of an acquisition transaction announced on November …
Tractor Supply Company filed a Form 8-K with the SEC on November 5, 2026, announcing the declaration of a cash dividend of $0.24 per share of common stock, payable December 8, 2026, to stockholders of record as of the close of business on November …
Chatham Lodging Trust filed a Form 8-K with the SEC on November 5, 2026, announcing the release of its results of operations for the three months ended September 30, 2026.
AIM ImmunoTech Inc. filed a Form 8-K with the SEC on November 5, 2026, furnishing a corporate presentation titled "The Ampligen Opportunity" and an accompanying press release under Regulation FD.
First Business Financial Services, Inc. filed a Form 8-K on November 5, 2026, disclosing that it had posted an investor presentation covering recent operating performance, financial condition, and business strategy for use in executive interactions with shareholders and analysts.
Kairos Pharma, Ltd. filed a Form 8-K on November 5, 2026, disclosing that the company has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 (carotuximab).
Digital Turbine, Inc. filed a Form 8-K on November 5, 2026, disclosing the appointment of Daniel Lentz as Chief Financial Officer, effective November 2, 2026, along with the terms of his employment agreement and equity awards.